Compass Pathways plc receives U.S. Food and Drug Administration priority designation for COMP360 in treatment-resistant depression, with rolling NDA review underway.
Written By: Vennela Reddy, BPharm
Reviewed By: Pharmacally Editorial Team
Compass Pathways plc announced that the U.S. Food and Drug Administration has granted a rolling review for its New Drug Application (NDA) for COMP360, a proprietary synthetic psilocybin formulation, and selected the therapy for the Commissioner’s National Priority Voucher (CNPV) program for treatment-resistant depression.
The CNPV program is designed to accelerate the development and review of therapies targeting significant unmet medical needs by enabling closer regulatory interaction.
It also provides a shortened review timeline of approximately one to two months following NDA submission, while maintaining established standards for safety, efficacy, and scientific rigor.
Chief Executive Officer Kabir Nath stated that the designation reflects both the urgent need for new treatment options in treatment-resistant depression and the strength of the clinical evidence supporting COMP360.
The decision comes amid broader efforts by the U.S. Food and Drug Administration to accelerate research and approval pathways for psychedelic therapies, particularly psilocybin-based treatments, following recent federal directives.
He emphasized that, despite the potential for expedited timelines, regulatory approval will depend on meeting the U.S. Food and Drug Administration’s established requirements for clinical evidence and compliance. The company also indicated it is progressing with commercial readiness alongside the regulatory review process.
COMP360 has demonstrated statistically significant and clinically meaningful results across two Phase 3 studies involving more than 1,000 participants with TRD, representing one of the largest clinical datasets for a classic psychedelic therapy in this indication.
Reported findings show a rapid onset of therapeutic effect, with improvements observed as early as one day after administration, and durability of response lasting up to six months in patients who achieved clinically meaningful benefit after one or two doses.
The therapy was generally well tolerated, with most treatment-emergent adverse events described as mild to moderate in severity and resolving within 24 hours.
Major depressive disorder continues to represent a substantial global health burden. The World Health Organization has projected that depression could become the leading cause of disease burden worldwide by 2030. In the United States alone, an estimated four million individuals with MDD are affected by TRD, a condition defined by inadequate response to at least two standard treatments and associated with persistent symptoms, reduced quality of life, increased comorbidities, and elevated risk of mortality and suicide.
Reference
About the Writer
Vennela Reddy, B Pharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.